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Abstract
Increased Body Mass Index (BMI) is associated with reduced all cause and cardiovascular (CV)
mortality in hemodialysis patients (HD), while CV risk increases with BMI in the general
population. In the general population obesity is associated with inflammation, decreased HDL,
increased LDL and triglycerides (TGs), all risk factors for CV disease. LDL does not predict CV
risk in HD, whereas increased C-reactive protein (CRP), interleukin-6 (IL-6), low HDL or apo AI
and increased fasting triglycerides (TG) do predict risk. Renal failure is associated with
dyslipidemia and inflammation in normal weight patients. We hypothesized that effects of obesity
may be obscured by virtue of renal failure in HD. We explored the relationship between adipose
tissue pools and distribution, i.e., subcutaneous adipose tissue (SAT) and visceral adipose tissue
(VAT) (measured by MRI) and measures of inflammation (CRP, IL-6, ceruloplasmin and α 1 acid
glycoprotein) HDL and LDL cholesterol, total TGs, apo A I, apo B, apo C II (an activator of
lipoprotein lipase (LPL)) and CIII (an inhibitor of LPL) and the adipokines, leptin and adiponectin
in 48 patients with prevalent HD. Total TG concentrations were positively correlated with VAT
controlled for age, sex and weight. Both apo C II and apo C III correlated only with VAT.
Adiponectin was inversely correlated with VAT and leptin was positively associated with SAT.
CRP and α 1 acid glycoprotein were weakly associated with SAT while ceruloplasmin was
strongly associated with VAT by multiple regression analysis. In contrast, apo B, LDL, apo A I
and HDL, and IL-6 were not correlated with any measure of body composition potentially
mitigating the effects of obesity in HD
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Introduction
While the relative risk of mortality is high among dialysis patients, one factor that predicts
survival is having a higher BMI (1,2,3). BMI is imprecise as a measure of body composition
and does not distinguish between muscle and fat mass. Nevertheless, the lack of an increase
in mortality among a population with a very high BMI (>35 kg/m2) strongly supports a
hypothesis that adiposity either in some way protects dialysis patients from mortality or that
risk factors normally associated with adiposity may not be associated with adiposity among
dialysis patients. Indices associated with lean body mass, such as total body water,
approximated by the volume of distribution of urea (V) independently predict survival (4,5).
Similarly, total body potassium, a measure of intracellular volume, predict survival in a
variety of chronic diseases (6,7,8). While the positive association between lean body mass
and survival can be explained by better preserved nutritional reserves or lower co-
morbidities, the basis for improved survival among obese patients is not obvious, although a
similar survival advantage is observed in patients with other chronic diseases (9).
Several cardiovascular risk factors are linked metabolically to body composition among
subjects having normal kidney function (10). LDL cholesterol levels and triglyceride levels
are positively associated with adiposity while HDL is inversely associated with adiposity
among subjects having normal kidney function (11). Inflammation, as assessed by plasma
CRP or IL-6 concentrations are also important cardiovascular risk factors both in dialysis
patients as well as in subjects with normal kidney function (12,13,14). CRP and IL-6 levels
are thought to be associated with adiposity in subjects with normal kidney function as a
result of inflammation within or caused by increased visceral adipose mass (15,16). A third
set of risk factors that are associated with adiposity both in the population having normal
kidney function as well as in patients having kidney failure are the adipokines, leptin and
adiponectin.
While some risk factors that predict cardiovascular disease among populations not having
kidney failure are no longer predictive in dialysis patients, such as hypertension and Low
Density Lipoprotein (LDL) cholesterol (17),other risk factors preserve their predictive
values, such as C reactive protein (CRP), IL-6 (12,13,18,), and low levels of High Density
Lipoprotein cholesterol (HDL) (17,19).
Elevated triglycerides (TG) are also associated with mortality among dialysis patients (19).
While TG levels are associated with adiposity among subjects having normal kidney
function, TG levels are also increased in dialysis patients by factors that may not be linked
to body composition, such as increased levels of lipoprotein lipase inhibitors such as
apolipoprotein C III (apo C III) (20,21) which is also linked both to insulin resistance and to
increased body adiposity
A third cluster of risk factors associated with body composition modulating cardiovascular
risk are adipokines (22,23). Leptin is secreted by adipocytes, and additionally is increased in
dialysis patients beyond what would be anticipated by total fat mass, primarily because of
reduced renal clearance of leptin (24,25), although the relationship to adiposity persists
within populations of patients having renal failure (24,25). Leptin is associated with insulin
resistance and increased circulating leptin has been directly associated with vascular disease
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(26,27,28,29). Circulating concentrations of a second adipokine, adiponectin, are inversely
proportion to fat mass (30), and specifically inversely related to the important visceral
adipose tissue mass (31,32). Adiponectin, like HDL has been reported to be inversely
associated with vascular disease in subjects with normal renal function (33). The
relationship between adiponectin levels and cardiovascular risk in patients having kidney
disease is controversial. High levels have been associated with increased cardiovascular risk
in some studies of dialysis patients (23) as well as in patients having stage 3 and 4 chronic
kidney disease (34) while high levels have been reported to be protective in other studies
(22).
In the present study, we measured body adipose tissue compartments and lean body mass
using MRI in a cohort of hemodialysis patients to investigate the relationship between the
relationship between adiposity and a number of risk factors for cardiovascular disease.
Methods
Institutional Review Board approval was obtained and all subjects signed an informed
consent prior to participation. Forty-eight prevalent hemodialysis patients consisting of 20
women and 28 men over the ages of 18 years were chosen so as to encompass a wide range
of body mass indices and ages. Thirty-seven patients were African American, 3 were non
black Hispanic, 3 were white, and 2 were Asian and 3 were other. Sixteen patients had
diabetes mellitus. For analysis of the effect of race patients were coded as black or non black
because of the small numbers in the other groups. All but one subject had been on
maintenance hemodialysis for at least 3 months prior to study. One subject had been on
dialysis for 2 months. They were studied on the day of a regularly scheduled hemodialysis
session approximately 3 hours prior to initiation of a dialysis treatment.
Following an overnight fast, body weight was measured to the nearest 0.1 kg (Weight
Tronix, New York), and height was measured to the nearest 0.5 cm by using a stadiometer
(Holtain, Crosswell, United Kingdom). Whole-body MRI scans were prepared by using a
1.5 Tesla scanners (6X Horizon; General Electric, Milwaukee) to evaluate muscle and fat
mass (35).
All assays were performed on serum obtained while the patient was in the fasting state. The
inflammatory markers C-reactive protein (CRP) interleukin-6 (IL-6), the long lived acute
phase proteins ceruloplasmin and, α 1 acid glycoprotein , the adipokines leptin and
adiponectin, and the apolipoproteins (Apo) apo A I, apo C II, apo C III, apo B, triglycerides,
total cholesterol and high density lipoprotein (HDL) low density lipoprotein (LDL)
cholesterol were measured. CRP, ceruloplasmin, apo A I apo B and α 1 acid glycoprotein
were measured with rate nephelometry using a Beckman Array automated nephelometer
(36). Apo C II and apo C III were measured nephelometrically using a Hitachi chemical
analyzer, leptin and adiponectin were measured by RIA (Millipore, St. Charles, MO). All
nephelometric measurements were made in duplicate in each of two optical systems. The
average of these values was used for calculations.
Statistical analysis methods
Data are presented as mean, standard deviation, median and range. Distribution of variables
for normality was assessed by Kolmogorov-Smirnov test (37). Variables that were non-
normally distributed were log transformed. Multivariate analysis employed multiple linear
regression analysis, with backward elimination (P < 0.1 for parameter retention in the
model) with biochemical markers as dependent variables. The independent variables were
subcutaneous adipose tissue mass (SAT) or visceral adipose tissue mass (VAT) or total
adipose tissue mass (TAT) measured by MRI adjusted for age, sex, presence of diabetes,
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weight and race. We also analyzed the effect of VAT on cardiovascular risk factors using
VAT as a categorical variable. We divided the population into tertiles and performed an
analysis of variance using Tukey's test for significance. We controlled for the effects of age,
race, and sex. A two-sided P-value < 0.05 was considered significant. JMP 5.0.1 (SAS
Campus Drive Cary, NC 27513 USA) was used for statistical analysis.
Results
Median BMI was 27.3 kg/m2 (19.4-46.6), median age was 54.5 years (33-80), median
weight 78.1 kg (43.1-120). Median total adipose tissue mass was 24.3 kg (6.2-57.9), median
subcutaneous adipose tissue mass was 20.3 kg (5.8-50.8), median visceral adipose tissue
mass was 3.25 kg (0.13-8.88), median skeletal muscle mass (SMM) was 23.3 kg (12.2-36.9).
Vintage ranged from two months to 15.3 years with a median vintage of 2.8 years. Residual
renal function expressed as urea clearance ranged from zero to 7.7 ml/min. Only 9 patients
had any urine output. Among those 9 the median residual clearance was 1.4 ml/min. Median
and range of risk factor are shown in Table 1.
Inflammatory Markers
By simple linear regression analysis, CRP was positively associated with SAT (r2 = 0.11, P
= 0.03, ceruloplasmin positively associated with VAT (r2 = 0.16 P = 0.01) and SAT (r2 = 0.2
P < 0.005) and α 1 acid glycoprotein was positively associated with SAT (r2 = 0.11, P =
0.03) (Table 2). After adjustment for demographic variables the association that remained
significant were between both α 1 acid glycoprotein and log CRP and SAT and between
ceruloplasmin and VAT (Table 3). IL-6 was not significantly related to any measure of
adiposity.
Lipid Markers
By univariate analysis triglycerides correlated with VAT (r2 = 0.27 P = 0.0006) (Figure 1)
(Table 2). By multiple regression analysis, TGs were significantly correlated only with VAT
after controlling for age, sex, and race (Table 3). When VAT was used as a categorical
variable, TGs were significantly greater in tertiles 3 and 2 when compared with patients in
the lowest tertile of VAT.
Apo C II correlated with VAT (r2 = 0.24 P = 0.001) and SAT (r2 = 0.18 P = 0.006) by
univariate analysis (Table 2). By multiple regression analysis apo C II correlated either with
VAT after adjustment for age, sex and race, (Table 3). Apo C II was significantly greater in
patients in the upper two tertiles of VAT compared to tertile I.
Similarly, apo C III correlated with VAT (r2 = 0.22 P = 0.0016) (Figure 2) and TAT (r2 =
0.2, P = 0.003) by univariate analysis Table 2). By multiple regression analysis apo C III
correlated positively with VAT after adjustment for age, sex, race, (Table 3). Apo C III was
significantly greater in patients in the upper two tertiles of VAT compared to tertile I.
Neither HDL cholesterol nor apo A I nor LDL cholesterol correlated with any measures of
body composition. In contrast to other lipid markers the r2 values were approximately zero
suggesting no effect of body composition on HDL or apo A I levels in these subjects.
Adipokines
Adiponectin was significantly and inversely associated with SAT (r2 = 0.20, P = 0.0027) and
VAT (r2 = 0.37 P < 0.0001). By multiple regression analysis, adiponectin was only
negatively associated with VAT (P<0.00001) and was not affected by sex or any other
anthropometric measurements (Table 3). The relationship between adiponectin and VAT
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(Figure 3) was essentially identical between men and women. Adiponectin was significantly
greater in patients in the first tertile of VAT compared with the second (P <0.01) and was
significantly greater in the first terile than in either the 2nd or the 3rd tertile.
Leptin (following log transformation) was positively associated with SAT (r2 = 0.766 P <
0.0001), VAT (r2 = 0.47, P <0.001) (Table 2) by univariate analysis but only with SAT by
multivariate analysis (r2 for the model 0.766, P < 0.0001) (Table 3).
Discussion
Mortality is increased with increasing BMI after a minimum mortality at BMIs between 23
and 26 in normal subjects (38,39). Adiposity, especially visceral adiposity, is associated
with cardiovascular disease (39,40), hypertension (41) and other cardiovascular risk factors
(increased triglycerides, LDL cholesterol, decreased HDL cholesterol and inflammation (10)
in patients with normal kidney function. Obesity identified as waist to hip ratio is also a risk
factor for incident chronic kidney disease (CKD) (42). Among those patients who develop
CKD, waist to hip ratio also was a risk factor for cardiovascular events (43). However, the
mean GFR in this cohort was 51.1 ml/min, so that extrapolation of risk to that of prevalent
dialysis patient population may not be applicable.
The causal link between cardiovascular mortality and adiposity is proposed at least in part to
be a consequence of alterations in blood lipid levels and in inflammation (15,16,44). In
contrast to patients having normal renal function, BMI is associated with increasing survival
among dialysis patients even at BMI values greater than 39 (1). Thus, obesity in dialysis
patients must either contribute some beneficial effect, or specific risk factors linking
mortality and adiposity must be mitigated.
We found that components of this relationship, especially the linkage between HDL
cholesterol and Apo A I, and to a lesser extent, the relationship between IL-6 and CRP and
elements of adiposity were obscured among dialysis patients. By contrast the relationship
between VAT and triglyceride-rich lipoproteins was essentially preserved as was the
relationship between adiposity and adipokine levels.
The dysplipidemia of CKD, specifically of the apo-B containing lipoproteins, is
characterized by reduced clearance (45). Decreased clearance of these lipoproteins is due in
part to intrinsic defects in the capacity of triglyceride-rich lipoproteins to act as appropriate
substrates for lipolytic enzymes (21) consistent with the presence of an intrinsic structural
change in lipoproteins making them less susceptible to lipolysis by LPL. Apo C III is an
inhibitor of the action of LPL on TG rich lipoproteins (46,47) and is increased in dialysis
patients (20). However while the levels of apo C III were significantly greater than reported
for normal subjects (48,49), we found that apo C III levels were associated with VAT within
these subjects, similar to the relationship described in patients without renal failure (50). By
contrast, LDL cholesterol was low for this population as a whole and was not significantly
associated with adiposity.
Inflammation is common among dialysis patients (51) and is well above levels observed in
non-dialysis populations (3,12). Inflammation is associated with the malnutrition,
inflammation, atherosclerosis (MIA) syndrome (52) providing a basis for inflammation in
non obese subjects, potentially obscuring an effect linked to adiposity. Among subjects
having normal kidney function, the association between adiposity and either CRP and IL-6
is quite strong, however the median values are significantly lower than we report for here for
dialysis patients (53). The upper tertile of CRP found among patients not having kidney
disease begins at 3 mg/L (54), a value below the median value among the dialysis patients
whom we studied. Similarly median IL-6 values were also well above the upper quartile (>
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2.28 pg/ml) among the non dialysis population (14). Axelsson reported an association
between truncal fat mass and serum IL-6 levels, however the r2 value was 0.044 (55). By
contrast we found a strong association between the more long lived acute phase protein
ceruloplasmin and VAT. Ceruloplasmin has been associated with central obesity in patients
not on dialysis (56). Serum IL-6 and CRP values are highly variable temporally in
hemodialysis patients, far more so than are the levels of α 1 acid glycoprotein or
ceruloplasmin (57) possibly contributing to the decrease in association between these more
variable proteins and the adipose pools. Thus, while inflammation and low HDL were
indeed found in this population, the risk was either not linked to adiposity at all or only
weakly linked to adiposity (CRP), primarily because of low HDL and increased
inflammation, at least as reported by short lived makers of inflammation, among lean
dialysis patients. The risk factors were present regardless of adiposity and present at a level
associated with the highest level of cardiovascular risk in populations not having kidney
failure. It is possible that other factors that we have not controlled for have obscured any
effects of body composition.
Adiposity remained associated with triglycerides and with the cardiovascular risk factor Apo
C III and visceral adiposity was inversely associated with adiponectin. In contrast to patients
without kidney failure, adiponectin has been found to be directly associated with mortality
in dialysis patients by some investigators, (23), indeterminate by some, (58), while a
protective effect has been noted by others (22). It is indeed possible that adioponectin is not
in the causal pathway linking body composition to outcome and is simply reflecting
adiposity, thus explaining the apparent salutary effect of high adiponectin in the population
of patients not having renal failure with a possible deleterious effect observed by some
investigators among populations of patients having kidney failure (23).
We previously established in a much larger group of patients (approximately 26,000) that
the relationship between HDL cholesterol and BMI was effaced as eGFR declined (59). The
main limitation of the current study is that it is small, however we have directly measured
both VAT, which is strongly associated with insulin resistance and dyslipidemia, as well as
SAT and found that many, but not all risk factors associated with increased adiposity are
increased in prevalent hemodialysis patients, regardless of total adiposity or visceral adipose
mass. If indeed these risk factors are on the causal pathway to cardiovascular mortality,
incremental risks imposed by these factors are not increased among obese dialysis patients.
However, other risk factors, specifically associated with triglyceride-rich lipoproteins (TG
and apo C III levels) retain the same qualitative relationship to body composition in dialysis
patients as they do in subjects having normal renal function. Why obese dialysis patients
avoid increased mortality risk despite the residual association between adiposity and these
risk factors remains to be established.
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Figure 1.
Relationship between serum triglycerides and visceral adipose tissue (VAT) measured by
MRI in prevalent hemodialysis patients.
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Figure 2.
Relationship between serum apo C III and visceral adipose tissue (VAT) measured by MRI
in prevalent hemodialysis patients.
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Figure 3.
Relationship between serum adiponectin level and VAT measured by MRI in prevalent
hemodialysis patients by sex. Men are represented by the open circles and women by the
open triangles.
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Table 1
Median and range of Risk Factors Among Dialysis Patients
CRP g/L 5.0(0.1-260)
IL-6 (pg/ml) 5.5 (1-22)
α 1 AG (mg/dl) 106(46-187)
Ceruloplasmin (mg/dl) 42(23-73)
HDL Cholesterol (mg/dl) 43 (8-79)
Apo A I (mg/dl) 131(89-239)
Triglycerides (mg/dl) 133(36-436)
Apo C III (mg/dl) 15.0(2.9-35.7)
Apo C II (mg/dl) 3.2(0.45-7.66)
LDL Cholesterol (mg/dl) 66(13-142)
Remnants Chol (mg/dl) 3.7(2.1-9.1)
Total Cholesterol (mg/dl) 157(83-236)
Apo B (mg/dl) 60.9(14.9-120)
Adiponectin (μg/ml) 18.4(5.9-59.4)
Leptin (ng/ml) 9.85(0.2-127.2)
Median and range of risk factors in hemodialysis patients.
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Table 2
Relationship between body composition and cardiovascular risk factors in hemodialysis
patients
Relationship between acute phase proteins and body composition by univariant analysis
VAT SAT
Log CRP NS P = 0.03 *
Log IL-6 NS NS
α 1 AG NS P = 0.03 *
Ceruloplasmin P = 0.01 P = 0.005
Relationship between adipokines and body composition by univariant analysis
VAT SAT
Log Leptin < 0.0001 < 0.0001
Log Adiponectin < 0.0001* 0.003
Relationship between lipids and body composition by univariant analysis
VAT SAT
Total Cholesterol NS 0.012 *
Triglycerides 0.0003 * 0.03
LDL NS NS
HDL NS NS
Apo C II 0.001 * 0.006
Apo C III 0.002 * 0.007
Apo B NS NS
Apo A I NS NS
Univariant relationship between groups of risk factors, inflammatory markers, adipokines, lipoprotein levels and and measures of adipose mass,
visceral adipose tissue (VAT), subcutaneous adipose tissue and (SAT) in hemodialysis patients. All tissue compartments are in kg and were
measured by magnetic resonance imaging.
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